Proteomics

Dataset Information

0

The HLA-Ligand-Atlas. A resource of natural HLA ligands presented on benign tissues

ABSTRACT: A use case of the benign HLA-Ligand-Atlas is the prioritization of tumor-associated targets for e.g. peptide vaccination. Based on three glioblastoma samples, we illustrated how many of these peptides are covered in the benign dataset. The experimental and computational workflow for the isolation and identification of the glioblastoma immunopeptidomes is the same, as for all samples included in the HLA Ligand Atlas. As the three glioblastoma samples are not included in the HLA Ligand Atlas dataset, they have been deposited under a separate submission.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Brain Glioblastoma Multiforme

SUBMITTER: Ana Marcu  

LAB HEAD: Hans-Georg Rammensee

PROVIDER: PXD020186 | Pride | 2021-04-16

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

<h4>Background</h4>The human leucocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Understanding the benign HLA ligand repertoire is a prerequisite to define safe T-cell-based immunotherapies against cancer. Due to the poor availability of benign tissues, if available, normal tissue adjacent to the tumor has been used as a benign surrogate when defining tumor-associated antigens. However,  ...[more]

Similar Datasets

Proteomics The HLA-Ligand-Atlas. A resource of natural HLA ligands presented on benign tissues
2021-04-16 | PXD019643 | Pride
Proteomics Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
2022-05-31 | PXD033935 | Pride
Proteomics,Multiomics The immunopeptidomic landscape of ovarian carcinoma
2017-11-02 | PXD007635 | Pride
Proteomics Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
2020-04-03 | PXD017149 | Pride
Proteomics Mapping the HLA ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
2019-03-12 | PXD009602 | Pride
Proteomics A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
2019-12-11 | PXD015947 | Pride
Proteomics Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia
2021-09-10 | PXD024871 | Pride
Proteomics Immunopeptidome of HeLa-CIITA cells silenced for TAX1BP1(T6BP) expression
2022-09-22 | PXD024417 | Pride
Proteomics CIITA-transduced glioblastoma cells uncover a rich repertoire of clinically relevant tumor-associated HLA-II antigens
2021-02-03 | PXD020079 | Pride
Other The landscape of the SARS-CoV-2 HLA-peptidome
2021-09-10 | PXD023614 | Pride